Weight-Loss Drug One-Year Data Enough For Safety and Efficacy – Cmte.
Executive Summary
One-year trial data for weight-control drugs provides enough information to establish efficacy and safety for approval, a majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee concluded Sept. 8
You may also be interested in...
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products
FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products
Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel
Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label